TEDA International Cardiovascular Hospital (TICH) Performs First EV-ICD Implantation – Reviving a Young Life from Syncope

TICH has successfully completed its first Extravascular Implantable Cardioverter-Defibrillator (EV-ICD) procedure on a teenage patient. This milestone elevates the hospital's capacity in preventing and treating sudden cardiac death, providing a new therapeutic option for young arrhythmia patients.

Sudden cardiac death represents one of the most common fatal outcomes of cardiovascular diseases. An Implantable Cardioverter-Defibrillator (ICD) serves as an effective preventive treatment. The recently introduced EV-ICD combines the core advantages of both transvenous and subcutaneous ICDs. Featuring an innovative substernal electrode placement design, it delivers complete defibrillation, cardioversion, and anti-tachycardia pacing without placing electrodes inside the heart or blood vessels, making it the ideal solution for this patient.

Prior to the surgery, TICH convened multidisciplinary consultations to repeatedly evaluate potential intraoperative challenges and develop comprehensive countermeasures. The procedure was ultimately completed successfully, with the patient recovering well and having returned to school.

As one of China's first medical institutions to perform EV-ICD implantations, TICH has not only established a long-term protective barrier for the patient but also demonstrated its technological breakthrough in precise arrhythmia treatment. This enables more domestic patients to benefit from international cutting-edge medical technology simultaneously.